AGY — Allergy Therapeutics Share News
0.000.00%
Last trade - 00:00- £300.80m
- £317.46m
- £55.04m
Allergy Therapeutics - First Patient Dosed in G308 Paediatric Trial
Brief: Allergy Therapeutics Submits MAA For Grass MATA MPL
Allergy Therapeutics - Notice of 2024 Annual General Meeting
Allergy Therapeutics - Audited Preliminary Results 2024
Brief: Allergy Therapeutics Commences Phase III Paediatric Trial
ZQ Capital Limited - Rule 19.6(c) Confirmation
Allergy Therapeutics - Commencement of Phase III Paediatric Trial
Allergy Therapeutics - Update on funding
Brief: Allergy Therapeutics Extends Cash Runway Into Late-October
Brief: Allergy Therapeutics Says Further Advancement Via Patient Cohorts In Phase I/IIa VLP Peanut PROTECT Trial
Brief: Allergy Therapeutics Extends Cash Runway Into Late September
Brief: Allergy Therapeutics Outlook HY Revenue GBP 21.6 Mln
Brief: Allergy Therapeutics Sees H2 Revenue At £21.6M
Allergy Therapeutics - Trading update for the year ended 30 June 2024
Allergy Therapeutics - Launch of new Company Long Term Incentive Plan
Allergy Therapeutics - Appointment of Non-Executive Director
Allergy Therapeutics - Progression of patient cohorts in PROTECT Trial
RCS - Allergy Therapeutics - Allergy Therapeutics presents findings at EAACI
Allergy Therapeutics - Director Resignation